ArticleInvestigational new drugs2019

The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers.

Philippe Collery et al.PubMed ↗Publisher ↗

No numbers read from the abstract.